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Abstract
Background and Purpose: Current management options for low-stage mixed malignant germ-cell testicular tu-
mors (MMGCT) after radical orchiectomy include surveillance, chemotherapy, or retroperitoneal lymph node
dissection (RPLND). The open RPLND is the surgical gold standard and has been duplicated laparoscopically
with confirmed diagnostic effectiveness; however, its therapeutic oncologic value in MMGCT has never been
proven. We present our laparoscopic RPLND (L-RPLND) data for low-stage MMGCT and paratesticular rhab-
domyosarcoma.
Patients and Methods: Retrospective chart reviews were performed for patients who underwent L-RPLND at
our institution for low clinical stage MMGCT and paratesticular rhabdomyosarcoma from May 2003 to De-
cember 2007. Patient data were compiled for surgical and clinical variables.
Results: A total of 26 L-RPLND procedures were completed, 3 for paratesticular rhabdomyosarcoma. Mean op-
erative time was 250 minutes (range 176–369 min); estimated blood loss was 145 mL (range 50–500 mL); lymph
node count was 23.8 (range 8–48); and hospital stay was 1.5 days (range 1–3 d). Four patients underwent
postchemotherapy L-RPLND for residual nodes (1.1–2.9 cm). There were no conversions to an open procedure,
blood transfusions, or operative complications. Chemotherapy was instituted in five of six patients with patho-
logic stage II disease. Mean follow-up was 23.7 months without retroperitoneal disease recurrence.
Conclusion: L-RPLND as a diagnostic and therapeutic tool provides the benefits of a minimally invasive ap-
proach to MMGCT. It is the procedure of choice at our institution for low-stage MMGCT and paratesticular
rhabdomyosarcoma.
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Introduction
THE CURRENT MANAGEMENT of low-stage mixed malignantgerm-cell testicular tumors (MMGCT) after radical or-
chiectomy consists of several options including an intense
surveillance protocol, platinum-based chemotherapy, or
modified template retroperitoneal lymph node dissection
(RPLND). With regard to surgery, laparoscopic RPLND (L-
RPLND) has demonstrated effectiveness as a retroperitoneal
staging tool.1–3 Recently, however, the L-RPLND has dupli-
cated open RPLND using full retroaortic and retrocaval dis-
sections with multi-institutional evidence that demonstrates
potential oncologic efficacy.1,4 Given the 30% incidence of
metastatic disease in the retroperitoneum for low-stage
MMGCT,5,6 70% of patients will undergo unnecessary ther-
apy. Attempts to minimize morbidity and long-term thera-
peutic consequences are essential.
The open RPLND is considered the surgical gold standard,5
although its morbidity may intimidate patients who are con-
sidering a laparoscopic approach. This perception could
change, because a recent report on the short-term morbidity
of the open procedure demonstrated improved operative
times, blood loss, and length of stay at a high-volume center.7
Laparoscopy, however, has become the standard of care
in various urologic oncology treatment regimens with dem-
onstrated efficacy, decreased morbidity, and improved pa-
tient satisfaction.8,9 L-RPLND has demonstrated improved
convalescence and quality of life compared with open
RPLND.10,11 In similar fashion, a report on robot-assisted L-
RPLND will continue to increase the minimally invasive na-
ture of the procedure.12
In a comprehensive review of the current status of L-
RPLND,13 the strengths and limitations of the approach were
portrayed and indicated that longer oncologic follow-up is
1Division of Urologic Surgery, Washington University in St. Louis, St. Louis, Missouri.
2Department of Urology, Columbia University School of Medicine, New York, New York.
necessary for this promising approach. Considering the po-
tential long-term adverse effects of primary chemotherapy,
including cardiovascular disease and secondary malignancy
reported to increase in testicular cancer survivors,14,15 treat-
ment opportunities with minimal morbidity should be ex-
plored. We present our experience with L-RPLND for low-
stage testicular cancer at Washington University with 2 years
of follow-up.
Patients and Methods
Retrospective chart reviews were performed for patients
who underwent L-RPLND at our institution for low-stage (I,
IIA/B) MMGCT and paratesticular rhabdomyosarcoma
from May 2003 to December 2007. Staging was performed
using the 2002 American Joint Committee on Cancer guide-
lines. The Human Studies Committee at Washington Uni-
versity approved the research protocol. Twenty-six patients
were identified. Patient data were compiled for surgical and
clinical variables, including: pre-orchiectomy tumor markers
(beta-human chorionic gonadotropin [-HCG], -fetoprotein
[AFP] and lactate dehydrogenase), orchiectomy data, L-
RPLND operative times, estimated blood loss (EBL), length
of hospital stay, number of resected lymph nodes with patho-
logic analysis, chemotherapeutic regimens, ejaculation sta-
tus, and imaging results.
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FIG. 1. Interaortocaval dissection. Note the complete excision of lymph tissue in the region during this right L-RPLND. 
FIG. 2. Para-aortic dissection. Similar clearing of lymph tissue during left L-RPLND.
Before L-RPLND, 19 clinical stage I patients with MMGCT
with normalization of tumor markers after orchiectomy and
4 postchemotherapy patients with residual masses were
identified. Most clinical stage I patients with MMGCT had
embryonal carcinoma and/or lymphovascular invasion in
the orchiectomy specimen. Three L-RPLNDs were per-
formed for paratesticular rhabdomyosarcoma, as ipsilateral
RPLND is recommended in adolescents to further stage and
manage the disease.16
There were no conversions to open RPLND and all pa-
tients without suspicious nodal involvement underwent uni-
lateral nerve-sparing modified template dissections as de-
scribed by Donohue and associates.17 Full retroaortic and
retrocaval dissections were undertaken in left and right dis-
sections, respectively, with interaortocaval node extraction
in each case (Figs. 1 and 2). The Harmonic Scalpel (Ethicon
EndoSurgery Inc, Cincinnati, OH) and Ligasure (Valleylab,
Boulder, CO) devices were used for the majority of the dis-
sections to limit clip placement and subsequent artifact on
follow-up imaging.
Suspicious nodes in patients with clinical stage I disease
were sent for frozen analysis. If positive, before 2006, the dis-
section was still performed in a similar fashion, and the op-
tion of chemotherapy was proposed for pathologic stage II
disease. Currently, on discovery of positive nodal status in-
traoperatively, a full bilateral dissection is performed. This
has been completed in one patient with metastatic germ-cell
tumor on frozen section analysis.
Follow-up of the patients consisted of history and phys-
ical examination, tumor markers, and chest radiography at
3-month intervals, with periodic CT imaging. After ap-
proximately 2 years, visit intervals were increased to 6
months and then annually according to physician prefer-
ence. Variation in the recommended follow-up pattern was
observed as some patients received follow-up at outside in-
stitutions.
Results
L-RPLND was successfully completed in all 26 patients.
Patient and operative data are shown in Table 1. There were
no conversions to an open procedure, blood transfusions, or
operative complications. Mean operative time was 250 min-
utes (range 176–369 min), EBL 145 mL (range 50–500 mL),
lymph node count 23.8 (range 8–48), and hospital stay 1.5
days (range 1–3 d). Mean follow-up was 23.7 months (range
3.2–55.3 months) without retroperitoneal disease recurrence
to date.
Postoperative complications included constipation and
emesis, one; lymphocele, four; deep vein thrombosis and
pulmonary embolism, one; chylous ascites, one; and ejacu-
latory dysfunction, three.
All three patients with paratesticular rhabdomyosarcoma
received chemotherapy with or without radiation as recom-
mended by the Intergroup Rhabdomyosarcoma Study
Group16 without recurrence to date.
Chemotherapy was instituted in five of six patients with
pathologic stage IIA MMGCT disease (Table 2) who com-
prised 32% of the clinical stage I population. Four patients
underwent postchemotherapy L-RPLND for residual nodes
(1.1 cm, 1.2 cm, 2.1 cm, 2.9 cm) without retroperitoneal re-
currence to date (Table 3). The patient with a 1.2 cm mass
who underwent a unilateral dissection demonstrates slowly
rising AFP and -HCG (both within normal limits) with neg-
ative imaging studies at 17 months of follow-up.
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TABLE 2. PATHOLOGIC STAGE IIA AFTER L-RPLND
Orchiectomy Retroperitoneal pathology
pathology (positive total nodes) Treatment Follow-up Recurrence
S, MT 2/19—EC, Ch, MT EP  4 50.2 mos None
EC 3/26—GCT BEP  3 17 mos None
S, EC, IMT, MT 1/30—S Surveillance 31.3 mos None
EC, YS 1/39—GCT EP  2 13 mos None
EC, YS 2/20—GCT EP  2 6.6 mos None
S, EC, IMT, MT 3/32—S BEP  2 4.3 mos None
S  seminoma; MT  mature teratoma; EC  embryonal carcinoma; Ch  choriocarcinoma; EP  etoposide; P  platinum-based chemo-
therapy regimen; no lymphovascular invasion in any specimens; GCT  metastatic germ cell tumor not specified; B  bleomycin; IMT 
immature teratoma; YS  yolk sac.
TABLE 1. PATIENT AND OPERATIVE DATA FOR L-RPLND
Mean age (years) 31
Orchiectomy
Right 12
Left 14
Pathology
Pure embryonal 2
Pure mature teratoma 1
Seminoma teratoma 1
Rhabdomyosarcoma 3
Mixed—19
With embryonal 19 (100%)
With seminoma 9 (47%)
With teratoma
Mature 9 (47%)
Immature 11 (58%)
With yolk sac 10 (53%)
ITGCN 14/23 (61%)
LV invasion 7/23 (30%)
Mean operative time (minutes) 250 (176–369)
(range)
Median EBL (mL) (range) 145 (50–500)
Mean hospital days (range) 1.5 (1–3)
Mean lymph nodes (range) 23.8 (8–48)
Follow-up (months) (range) 23.7 (3.2–55.3)
L-RPLND  laparoscopic retroperitoneal lymph node dissection;
ITGCN  intratubular germ-cell neoplasia; LV  lymphovascular;
EBL  estimated blood loss.
Discussion
L-RPLND has been performed at our institution since 2003
for persons with low-stage MMGCT of the testis. None of the
patients with pathologic stage I disease have demonstrated re-
current disease in the retroperitoneum, consistent with previ-
ous reports1–4 of L-RPLND as an accurate diagnostic staging
tool. The ability to appropriately stage the retroperitoneum is
evidenced by lack of retroperitoneal recurrence, although the
oncologic efficacy of the procedure may be questioned, given
that five of six patients with pathologic stage II disease un-
derwent chemotherapy. The solitary patient undergoing sur-
veillance demonstrates no recurrence at 31.3 months (1 of 30
lymph nodes with microscopic metastatic seminoma).
It has been necessary for institutions using advanced lap-
aroscopic techniques to pool data on the limited numbers of
patients with pathologic stage II disease undergoing surveil-
lance to potentially demonstrate surgical equivalence. Hamil-
ton and Finelli13 recently reviewed the status of L-RPLND
and, although the technique has significant potential, the
long-term oncologic data are not sufficient for comparison
with the open procedure. In the transition from a staging tool
to a therapeutic option, chemotherapy has continued to be
instituted for pathologic stage II disease, thus clouding the
true effectiveness of the procedure. The review cites benefits
of decreased operative time, cost, and morbidity; however, if
an inadequate dissection is performed, these are negated.
Our current practice is a full bilateral dissection in the set-
ting of intraoperative nodal positivity along with complete
evacuation of lymph tissue posterior to the great vessels, sim-
ilar to the open procedure. The open RPLND has demon-
strated, in a randomized fashion, efficacy in eradicating
retroperitoneal disease in patients with pathologic stage II
disease; surveillance and chemotherapy are used only when
relapse occurs (50% of patients) with similar cure rates.18
Given the duplication of the open technique,4 we and oth-
ers offer potential oncologic efficacy similar to the open pro-
cedure, although this is yet unproven. Thus, the status of rec-
ommending L-RPLND at laparoscopic institutions using
advanced laparoscopic techniques as a sole treatment for
pathologic stage II disease remains unclear. Indeed, longer
follow-up of the limited numbers of patients forgoing che-
motherapy in the setting of positive lymph nodes needs to
be conducted as well as future studies on the efficacy of L-
RPLND alone for pathologic stage II disease.
L-RPLND in postchemotherapy patients has an increased
complication rate19; therefore, patient selection is important.
We performed postchemotherapy L-RPLND in four patients
for 1.1 to 2.9 cm masses. All patients had three cycles of
bleomycin, etoposide, and platinum chemotherapy before
surgery and underwent uncomplicated procedures, with dis-
charge on postoperative day 1. Lymph nodes resected
ranged from 27 to 37. Three specimens demonstrated mature
teratoma; the other was metastatic seminoma, although the
original tumor did contain elements of seminoma, teratoma,
and embryonal carcinoma. Mean operative time was 275
minutes. Mean follow-up is 12.7 (5.8-17.5) months.
The single postoperative complication occurred after a bi-
lateral dissection for a 2.1 cm left para-aortic mass in a pa-
tient with a mildly elevated AFP level. A large lymphocele
developed in the patient that caused inferior vena caval ob-
struction and bilateral deep vein thromboses as well as pul-
monary embolism. After lymphocele drainage, anticoagula-
tion, and various temporary venous filter placements, the
patient recovered and is disease free.
Also, one patient demonstrates rising AFP and -HCG lev-
els (both within normal limits) with negative imaging at 17
months of follow-up after undergoing a left modified tem-
plate L-RPLND for a 1.2 cm residual mass; pathologic eval-
uation demonstrated metastatic teratoma in 1 of 37 lymph
nodes. These data suggest postchemotherapy L-RPLND is
feasible; however, the risk of postoperative complications
may be increased, and close follow-up is necessary.
Ipsilateral RPLND is currently recommended as part of
the staging process in adolescents with paratesticular rhab-
domyosarcoma.16 It also guides further treatment strategies
based on recommendations from the Intergroup Rhabdo-
myosarcoma Study Group. Pathologic findings at L-RPLND
in two of three patients were negative for malignancy; how-
ever, one patient did demonstrate metastatic embryonal
rhabdomyosarcoma in 3 of 48 lymph nodes, necessitating ra-
diation therapy in addition to standard chemotherapy (vin-
cristine, actinomycin-D, and cyclophosphamide) with no ev-
idence of metastatic disease at 21.1 months follow-up.
To our knowledge, only one other report demonstrates L-
RPLND as an option for children with paratesticular rhab-
domyosarcoma.20 Although a rare tumor, we recommend
staging the retroperitoneum in cases of adolescent parates-
ticular rhabdomyosarcoma using L-RPLND.
Limitations of our study include its retrospective nature
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TABLE 3. POST-CHEMOTHERAPY L-RPLNDa
Residual OR time EBL Follow-up
mass (min) U/B (mL) Pathology HD (months) Recurrence
1.1 cm 317 U 100 3/34 MT 1 10.4 None
1.2 cm 200 U 50 1/37 MT 1 17.3 Rising, normal range
AFP/-HCG; no
radiographic
evidence of
recurrence
2.1 cm 369 B 150 2/35 S 1 5.8 None
2.9 cm 214 U 75 3/27 MT 1 17.5 None
aNo further chemotherapy administered.
OR  operating room; U/B  unilateral or bilateral dissection; EBL  estimated blood loss; HD  hospital days; MT  mature teratoma;
AFP/-HCG  -fetoprotein/ human chorionic gonadotropin; S  seminoma.
and the limited 2-year duration of follow-up. Long-term on-
cologic data collection will be necessary as well as with-
holding chemotherapy in pathologic stage II patients; our se-
ries only contains one such person. We do, however, confirm
the feasibility of the procedure at an experienced laparo-
scopic center with minimal perioperative morbidity and hos-
pital stay.
Conclusion
L-RPLND as a diagnostic and therapeutic tool provides
the benefits of a minimally invasive approach to MMGCT;
however, the oncologic efficacy of L-RPLND continues to
need further investigation. It is the procedure of choice at
our institution for low-stage MMGCT and paratesticular
rhabdomyosarcoma. In selected patients, L-RPLND is also
safely used following chemotherapy. Further multi-institu-
tional efforts are needed to conclusively demonstrate the ef-
ficacy of advanced, minimally invasive treatments for pa-
tients with testis cancer.
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Abbreviations Used
CT  computed tomography
AFP  -fetoprotein
-HCG  -human chorionic gonadotropin
CT  computed tomography
EBL  estimated blood loss
L-RPLND  laparoscopic retroperitoneal lymph node
dissection
MMGCT  mixed malignant germ-cell testicular 
tumors
RPLND  retroperitoneal lymph node dissection

